Skip to main content

Table 3 Clinical remission according to treatment group in patients with oligoarticular JIA

From: Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

  SDMARD alone
n = 66
SDMARD combined
n = 18
SDMARD BDMARD combined
n = 25
BDMARD alone
n = 3
Clinical remission
n = 112
p
Persistent 61 (92) 13 (72) 17 (68) 1 (33) 92 (46) 0.003
Comorbidities b absence, n (%) 58 (88) 15 (83) 23 (92) 1 (33) 97 (87) 0.042
Synthetic DMARD a, n (%)
 Metotrexate 53 (80) 9 (50) 8 (50) 0 70 (35) 0.025
First DMARD course c, n (%) 44 (67) 6 (28) 11 (44) 0 60 (54) 0.014
DMARD dose tapering a, n (%) 51 (77) 8 (44) 15 (60) 3 (100) 77 (69) 0.024
  1. SDMARD Synthetic disease modifying drug, BDMARD Biologic disease modifying drug, JIA Juvenile idiopathic arthritis, n Number;
  2. ap < 0,05 Statistically significant differences using the χ2 test
  3. bComorbidities other than uveitis and not related to drug toxicity
  4. cFirst DMARD course = DMARD dispensed in the first place, chronologically